Practice Points
A Health Data Space for patients, science, policy and industry: can Europe make it work?
The answers to so many pressing questions about cancer, and about how best to diagnose and manage the disease and care for patients, lie waiting to be revealed through analysis…
Born to be walkers? How to stay healthy in a sedentary world
Humans have been endurance runners and walkers for at least 2 million years. Walking and running are our two main gaits. Whether we are more predisposed for the former or…
Project ECHO: spreading access to specialist care through democratising knowledge
Manjula (not her real name) was deeply surprised when she was diagnosed with stage 3 stomach cancer at the age of 52. She was healthy and had no other ailments.…
Getting the message across: we need to learn from the Covid experience
One of the big lessons of the Covid pandemic has been the critical importance of good communication – how challenging it is to get complex medical information across to the…
Cervical cancer: Rebuilding a nation’s broken trust in their screening service
Ireland’s cervical cancer screening programme ‘CervicalCheck’ has been under the microscope since April 2018, when it was revealed that some women diagnosed with invasive cervical cancer were not told that…
Molecular diagnostics and NGS in the clinic: where are we and where do we need to go?
The development of next generation sequencing (NGS) has been a game changer for our understanding of genetics, and in turn for many aspects of biomedicine. This includes cancer, where it…
Covid-19 pandemic: information and resources to support the cancer care community
As soon as the first analysis of the risk for severe COVID-19 in patients with cancer was published online in Lancet Oncology on February 14th, 2020, it emerged that these…
Delivering the best cancer care during the pandemic
Key messages from the e-ESO faculty On March 18, the European School of Oncology presented an interactive webinar on how to do this, drawing on the limited data available, the…
Tackling resistance to anti-EGFR therapies, from challenges to re-challenge
Since their first approval and use, more than 15 years ago, inhibitors of the Epidermal Growth Factor Receptor (EGFRi) have revolutionized the clinical practice and the prognosis for cancer patients,…